^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
Xatmep (methotrexate oral solution)
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Azurity Pharma
Drug class:
THF dehydrogenase inhibitor, Dihydrofolic acid reductase inhibitor
Related drugs:
2ms
A Study to Investigate LP-118, Ponatinib, Vincristine and Dexamethasone in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL) (clinicaltrials.gov)
P1/2, N=15, Recruiting, University of Chicago | Active, not recruiting --> Recruiting
Enrollment open
|
Iclusig (ponatinib) • vincristine • Xatmep (methotrexate oral solution)
2ms
A Study to Investigate LP-118, Ponatinib, Vincristine and Dexamethasone in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL) (clinicaltrials.gov)
P1/2, N=15, Active, not recruiting, University of Chicago | Not yet recruiting --> Active, not recruiting | N=33 --> 15 | Initiation date: Apr 2025 --> Sep 2024
Enrollment closed • Enrollment change • Trial initiation date
|
Iclusig (ponatinib) • vincristine • Xatmep (methotrexate oral solution)
6ms
A Study to Investigate LP-118, Ponatinib, Vincristine and Dexamethasone in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL) (clinicaltrials.gov)
P1/2, N=33, Not yet recruiting, University of Chicago | Initiation date: Apr 2024 --> Apr 2025
Trial initiation date
|
Iclusig (ponatinib) • vincristine • Xatmep (methotrexate oral solution)
8ms
Drug Concentrations in Breast Milk and Prediction of Blood Levels of the Breastfed Infants (clinicaltrials.gov)
P=N/A, N=39, Completed, The Hospital for Sick Children | Recruiting --> Completed | N=304 --> 39
Trial completion • Enrollment change
|
methotrexate • Xatmep (methotrexate oral solution)
10ms
A Study to Investigate LP-118, Ponatinib, Vincristine and Dexamethasone in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL) (clinicaltrials.gov)
P1/2, N=33, Not yet recruiting, University of Chicago
New P1/2 trial
|
Iclusig (ponatinib) • vincristine • Xatmep (methotrexate oral solution)
1year
SWOG-S1318: Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia (clinicaltrials.gov)
P2, N=53, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Oct 2023 --> Sep 2024
Trial completion date
|
ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase) • PDGFRA (Platelet Derived Growth Factor Receptor Alpha) • FGFR (Fibroblast Growth Factor Receptor) • PDGFRB (Platelet Derived Growth Factor Receptor Beta) • CD4 (CD4 Molecule) • CSF1R (Colony stimulating factor 1 receptor)
|
ABL2 fusion
|
dasatinib • Blincyto (blinatumomab) • methotrexate • vincristine • mercaptopurine • Xatmep (methotrexate oral solution)
2years
SWOG-S1318: Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia (clinicaltrials.gov)
P2, N=57, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jun 2023 --> Sep 2023 | Trial primary completion date: Jun 2023 --> Jun 2022
Trial completion date • Trial primary completion date
|
ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase) • PDGFRA (Platelet Derived Growth Factor Receptor Alpha) • FGFR (Fibroblast Growth Factor Receptor) • PDGFRB (Platelet Derived Growth Factor Receptor Beta) • CD4 (CD4 Molecule) • CSF1R (Colony stimulating factor 1 receptor)
|
ABL2 fusion
|
dasatinib • Blincyto (blinatumomab) • methotrexate • vincristine • mercaptopurine • Xatmep (methotrexate oral solution)
3years
SWOG-S1318: Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia (clinicaltrials.gov)
P2, N=58, Active, not recruiting, National Cancer Institute (NCI) | Suspended --> Active, not recruiting
Clinical • Enrollment closed
|
ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase) • PDGFRA (Platelet Derived Growth Factor Receptor Alpha) • FGFR (Fibroblast Growth Factor Receptor) • PDGFRB (Platelet Derived Growth Factor Receptor Beta) • CD4 (CD4 Molecule) • CSF1R (Colony stimulating factor 1 receptor)
|
ABL2 fusion
|
dasatinib • Blincyto (blinatumomab) • methotrexate • vincristine • mercaptopurine • Xatmep (methotrexate oral solution)
almost4years
Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia (clinicaltrials.gov)
P2, N=58, Suspended, National Cancer Institute (NCI) | Recruiting --> Suspended
Clinical • Trial suspension
|
ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase) • PDGFRA (Platelet Derived Growth Factor Receptor Alpha) • FGFR (Fibroblast Growth Factor Receptor) • PDGFRB (Platelet Derived Growth Factor Receptor Beta) • CD4 (CD4 Molecule) • CSF1R (Colony stimulating factor 1 receptor)
|
ABL2 fusion
|
dasatinib • Blincyto (blinatumomab) • methotrexate • vincristine • prednisone • mercaptopurine • Xatmep (methotrexate oral solution)
almost4years
Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia (clinicaltrials.gov)
P2, N=58, Recruiting, National Cancer Institute (NCI) | Trial primary completion date: Jul 2021 --> Jun 2022
Clinical • Trial primary completion date
|
ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase) • PDGFRA (Platelet Derived Growth Factor Receptor Alpha) • FGFR (Fibroblast Growth Factor Receptor) • PDGFRB (Platelet Derived Growth Factor Receptor Beta) • CD4 (CD4 Molecule) • CSF1R (Colony stimulating factor 1 receptor)
|
ABL2 fusion
|
dasatinib • Blincyto (blinatumomab) • methotrexate • vincristine • prednisone • mercaptopurine • Xatmep (methotrexate oral solution)
over4years
Preventing Nephrotoxicity and Ototoxicity From Osteosarcoma Therapy (clinicaltrials.gov)
P2, N=13, Completed, Children's Hospital of Philadelphia | Active, not recruiting --> Completed
Clinical • Trial completion
|
KIM1 (Kidney injury molecule 1)
|
cisplatin • Xatmep (methotrexate oral solution) • methotrexate IV
Share via
